ETF Managers Group’s Cardlytics CDLX Stock Holding History

ETF Managers Group’s Portfolio CDLX Stock Details CDLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-1,013	Closed	-$1.29M	–	683
2021 Q2	$1.29M	Buy	+1,013	New	+$1.14M	0.02%	259

Other funds holding CDLX

CIP

CAS Investment Partners Westport, Connecticut $1.88B AUM 2.5% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

ACM

Alua Capital Management New York $103M AUM 11.88% 1-Year Est. Return

KGAMU

KPS Global Asset Management (UK) London, United Kingdom $620M AUM 14.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

ETF Managers Group's CDLX Position: Q3 2021 in Review

ETF Managers Group sold out of Cardlytics (CDLX) in Q3 2021, closing a stake of 1,013 shares — an estimated $1.29M sold.

ETF Managers Group first reported a position in CDLX in Q2 2021 and held it in 1 quarter. The position peaked at $1.29M in Q2 2021. 164 funds tracked by Wall St. Rank hold CDLX as of Q3 2021.

ETF Managers Group reported no remaining Cardlytics position as of Q3 2021 after selling out during the quarter.
ETF Managers Group sold 1,013 Cardlytics shares in Q3 2021, an estimated $1.29M.
ETF Managers Group first reported a position in Cardlytics in Q2 2021 and held it in 1 quarter.
ETF Managers Group's Cardlytics position peaked at $1.29M in Q2 2021.
164 funds tracked by Wall St. Rank held Cardlytics as of Q3 2021.

Based on ETF Managers Group's 13F filing for Q3 2021, filed 15 Nov 2021.